Dupont Capital Management Corp Buys Shares of 8798 Boston Scientific Corporation (BSX)

Postado Novembro 14, 2017

Janus Henderson Group PLC now owns 38,862,599 shares of the medical equipment provider's stock worth $1,077,270,000 after buying an additional 38,690,577 shares in the last quarter.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Boston Scientific Corporation by 2.8% in the second quarter. Amalgamated Bank expanded its investment by buying 3,580 shares an increase of 2.2% as of 09/30/2017.

As of the end of the quarter American International Group Inc had sold 21,527 shares trimming its stake by 5.0%. Bronfman E.L. Rothschild L.P. raised its position in Boston Scientific Corporation by 14.3% in the 2nd quarter. Vanguard Group Inc. now owns 93,657,300 shares of the medical equipment provider's stock worth $2,596,181,000 after buying an additional 2,522,556 shares in the last quarter. The value of the investment in (BSX) went from $11,937,000 to $11,934,000 decreasing 0.0% for the reporting period. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider's stock valued at $141,000 after buying an additional 3,100 shares during the last quarter. Boston Scientific Corporation's revenue was up 5.6% on a year-over-year basis. equities research analysts expect that Boston Scientific Corporation will post 1.25 earnings per share for the current fiscal year. Sivik Global Healthcare LLC now controls 260,000 shares worth $7,584,000.

In related news, SVP Maulik Nanavaty sold 57,031 shares of the company's stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $28.42, for a total value of $440,510.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The stock was sold at an average price of $27.46, for a total transaction of $277,455.84. Following the completion of the transaction, the executive vice president now owns 164,681 shares of the company's stock, valued at approximately $4,647,297.82. Company insiders own 0.74% of the company's stock.

Shares of Boston Scientific Corporation (BSX) traded up $0.09 during trading on Tuesday, reaching $28.45. Trading volume for Boston Scientific Corporation was 4.72 Million in its previous trading session. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58.

Boston Scientific Corporation (NYSE:BSX) touched its 1-Year High price of $29.93 on 10/23/17 and its 1-Year Low price of $19.67 on 12/01/16. On average, equities research analysts predict that Boston Scientific Corp. will post $1.10 earnings per share for the current year.

Price-to-free-cash-flow (P/FCF) of 49.29 gives an overview of the equity valuation for Boston Scientific Corporation. Boston Scientific Corp. The firm had revenue of $2.11 billion for the quarter, compared to the consensus estimate of $2.07 billion. During the same period in the prior year, the firm earned $0.24 EPS. The company's revenue for the quarter was up 5.6% compared to the same quarter past year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US & worldwide trademark & copyright laws. The original version of this piece can be read at https://stocknewstimes.com/2017/11/14/boston-scientific-corporation-bsx-shares-sold-by-tokio-marine-asset-management-co-ltd.html.

BSX has been the subject of several research reports. Also, the Hold rating count is 2 as of 11/13/17.

November 7 investment analysts at Royal Bank Of Canada left the stock rating at "Buy" projecting a price of $31.00. The count of Hold ratings in that period was 1. Cowen and Company reissued a "buy" rating and issued a $32.00 target price (up previously from $31.00) on shares of Boston Scientific Corporation in a research report on Friday, July 28th. Canaccord Genuity released research on BSX with an initial rating of "Buy". The company has an average rating of "Buy" and an average target price of $30.77.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Want to see what other hedge funds are holding BSX?